|
1
|
Shiraha H, Yamamoto K and Namba M: Human
hepatocyte carcinogenesis (review). Int J Oncol. 42:1133–1138.
2013.PubMed/NCBI
|
|
2
|
Zimonjic DB and Popescu NC: Role of DLC1
tumor suppressor gene and MYC oncogene in pathogenesis of human
hepatocellular carcinoma: Potential prospects for combined targeted
therapeutics (review). Int J Oncol. 41:393–406. 2012.PubMed/NCBI
|
|
3
|
Kirstein MM and Vogel A: The pathogenesis
of hepatocellular carcinoma. Dig Dis. 32:545–553. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Meng X, Franklin DA, Dong J and Zhang Y:
MDM2-p53 pathway in hepatocellular carcinoma. Cancer Res.
74:7161–7167. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kawaguchi M and Kataoka H: Mechanisms of
hepatocyte growth factor activation in cancer tissues. Cancers
(Basel). 6:1890–1904. 2014. View Article : Google Scholar
|
|
6
|
Xie B and Dong JH: HGF/c-Met and
metastasis of hepatocellular carcinoma. Zhonghua Gan Zang Bing Za
Zhi. 13:396–398. 2005.In Chinese. PubMed/NCBI
|
|
7
|
Espinosa AM, Alfaro A, Roman-Basaure E,
Guardado-Estrada M, Palma Í, Serralde C, Medina I, Juárez E,
Bermúdez M, Márquez E, et al: Mitosis is a source of potential
markers for screening and survival and therapeutic targets in
cervical cancer. PLoS One. 8:e559752013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Lai MW, Chen TC, Pang ST and Yeh CT:
Overexpression of cyclin-dependent kinase-associated protein
phosphatase enhances cell proliferation in renal cancer cells. Urol
Oncol. 30:871–878. 2012. View Article : Google Scholar
|
|
9
|
Li T, Xue H, Guo Y and Guo K: CDKN3 is an
independent prognostic factor and promotes ovarian carcinoma cell
proliferation in ovarian cancer. Oncol Rep. 31:1825–1831.
2014.PubMed/NCBI
|
|
10
|
Taylor KJ, Sims AH, Liang L, Faratian D,
Muir M, Walker G, Kuske B, Dixon JM, Cameron DA, Harrison DJ and
Langdon SP: Dynamic changes in gene expression in vivo predict
prognosis of tamoxifen-treated patients with breast cancer. Breast
Cancer Res. 12:R392010. View
Article : Google Scholar : PubMed/NCBI
|
|
11
|
Drozdov I, Bornschein J, Wex T, Valeyev
NV, Tsoka S and Malfertheiner P: Functional and topological
properties in hepa-tocellular carcinoma transcriptome. PLoS One.
7:e355102012. View Article : Google Scholar
|
|
12
|
Xing C, Xie H, Zhou L, Zhou W, Zhang W,
Ding S, Wei B, Yu X, Su R and Zheng S: Cyclin-dependent kinase
inhibitor 3 is over-expressed in hepatocellular carcinoma and
promotes tumor cell proliferation. Biochem Biophys Res Commun.
420:29–35. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Li H, Jiang X, Yu Y, Huang W, Xing H, Agar
NY, Yang HW, Yang B, Carroll RS and Johnson MD: KAP regulates ROCK2
and Cdk2 in an RNA-activated glioblastoma invasion pathway.
Oncogene. 34:1432–1441. 2015. View Article : Google Scholar
|
|
14
|
Yeh CT, Lu SC, Chen TC, Peng CY and Liaw
YF: Aberrant transcripts of the cyclin-dependent kinase-associated
protein phosphatase in hepatocellular carcinoma. Cancer Res.
60:4697–4700. 2000.PubMed/NCBI
|
|
15
|
Nalepa G, Barnholtz-Sloan J, Enzor R, Dey
D, He Y, Gehlhausen JR, Lehmann AS, Park SJ, Yang Y, Yang X, et al:
The tumor suppressor CDKN3 controls mitosis. J Cell Biol.
201:997–1012. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Hou J, Liu Z and Gu F: Epidemiology and
prevention of hepatitis B virus infection. Int J Med Sci. 2:50–57.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yu Y, Jiang X, Schoch BS, Carroll RS,
Black PM and Johnson MD: Aberrant splicing of cyclin-dependent
kinase-associated protein phosphatase KAP increases proliferation
and migration in glioblastoma. Cancer Res. 67:130–138. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Lee SW, Reimer CL, Fang L, Iruela-Arispe
ML and Aaronson SA: Overexpression of kinase-associated phosphatase
(KAP) in breast and prostate cancer and inhibition of the
transformed phenotype by antisense KAP expression. Mol Cell Biol.
20:1723–1732. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
McCubrey JA, Steelman LS, Franklin RA,
Abrams SL, Chappell WH, Wong EW, Lehmann BD, Terrian DM, Basecke J,
Stivala F, et al: Targeting the RAF/MEK/ERK, PI3 K/AKT and p53
pathways in hematopoietic drug resistance. Adv Enzyme Regul.
47:64–103. 2007. View Article : Google Scholar
|
